Your session is about to expire
← Back to Search
Anti-metabolites
BST-236 for Acute Myeloid Leukemia (ELPIS Trial)
Phase 2
Waitlist Available
Research Sponsored by BioSight Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28-35 of induction/re induction course
Awards & highlights
ELPIS Trial Summary
This trial will test a new cancer drug, BST-236, on patients with newly diagnosed AML who are too old or sick for standard chemotherapy. The goal is to see if BST-236 is more effective than what has been seen in similar patients in the past.
Eligible Conditions
- Acute Myeloid Leukemia
ELPIS Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 28-35 of induction/re induction course
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28-35 of induction/re induction course
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Complete Remission
ELPIS Trial Design
1Treatment groups
Experimental Treatment
Group I: BST-236Experimental Treatment1 Intervention
BST-236 Intravenous, 4.5 g/m2/d or 2.5 g/m2/d, for 6 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BST-236
2018
Completed Phase 2
~70
Find a Location
Who is running the clinical trial?
BioSight Ltd.Lead Sponsor
3 Previous Clinical Trials
140 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger